GTBP GT BIOPHARMA INC Product Launches 8-K Filing 2025 - First Patient Dosed GT Biopharma, Inc. announced that the first patient was dosed in the Phase 1 Trial of GTB-3650, a treatment for blood cancers, on January 27, 2025.Get access to all SEC 8-K filings of the GT BIOPHARMA INC